Profile: InNexus Biotechnology Inc. is a drug development company that delivers monoclonal antibodies based on the DXL™ technology, which improves the potency of existing antibody products. Our DXL625 is a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-hodgkins lymphoma. Our DXLr120 is a recombinant DXL™ anti-CD20 antibody being developed for the treatment of B cell non-hodgkins lymphoma cancer. Our DXLmouse™ is a genetically modified mouse in which antibodies are produced naturally in response to antigen.